Victoza is FDA-approved for promoting glycemic control in patients with type 2 diabetes (adults and children aged 10 years or older) as an adjunct to dietary modifications and exercise
seek urgent medical advice for right upper quadrant pain or jaundice Diabetic retinopathy complications : Patients with pre-existing retinopathy should have regular ophthalmological monitoring, as rapid glycaemic improvement may temporarily worsen retinal disease Renal impairment : Dehydration from gastrointestinal side effects can affect kidney function, particularly in vulnerable patients Injection site reactions (redness, itching, bruising) are common but usually mild
Handling should only be performed by qualified laboratory professionals in controlled research settings with appropriate institutional authorisations in place
Considering the significant negative impact of PAD in diabetic patients, international clinical guidelines have recommended using glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) in individuals with type 2 diabetes and PAD to reduce the risk of major adverse cardiovascular events
Endocrine (2015) 48(1):10715.10.1007/s12020-014-0361-4 12 GilbertMPMarreMHolstJJGarberABaeresFMThomsenHet alComparison of the long-term effects of liraglutide and glimepiride monotherapy on bone mineral density in patients with type 2 diabetes
VIEW PRODUCT CATALOGUE